Amneal Makes First Biosimilar Launch With US Bevacizumab
Alymsys Rival To Avastin, Developed By mAbxience, Is Introduced In US
Amneal says it has “officially entered the US biosimilar market” after introducing its Alymsys biosimilar bevacizumab rival to Avastin. The biosimilar launch represents the first of three expected for Amneal in 2022, following US FDA approvals earlier this year.
